| Kurt Emil Wehberg, MD | |
|
30265 Commerce Dr Unit 103, Millsboro, DE 19966-3594 | |
| (302) 934-6514 | |
| Not Available |
| Full Name | Kurt Emil Wehberg |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 32 Years |
| Location | 30265 Commerce Dr Unit 103, Millsboro, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275507535 | NPI | - | NPPES |
| 231431200 | Medicaid | MD |
| Facility Name | Location | Facility Type |
|---|---|---|
| Peninsula Home Care, Llc | Salisbury, MD | Home health agency |
| Nanticoke Memorial Hospital | Seaford, DE | Hospital |
| Beebe Medical Center | Lewes, DE | Hospital |
| Peninsula Regional Medical Center | Salisbury, MD | Hospital |
| Atlantic General Hospital | Berlin, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tidalhealth Specialty Care Llc | 7113340845 | 182 |
| Tidalhealth Specialty Care Llc | 7113340845 | 182 |
News Archive
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.
Nature Methods published (online) a comparative study of leading Protein-Protein Interaction (PPI) Networks.
Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.
Researchers in Doernbecher Children's Hospital at Oregon Health & Science University will begin a Phase I clinical trial using stem cells in infants and children with a rare neurodegenerative disorder that affects infants and children.
INVO Bioscience, Inc., a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the SEC declared its Registration Statement on Form S-1 filed on December 21, 2009 effective on December 30, 2009.
› Verified 9 days ago
| Entity Name | Tidalhealth Peninsula Regional, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184832040 PECOS PAC ID: 3072509702 Enrollment ID: O20040420001571 |
News Archive
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.
Nature Methods published (online) a comparative study of leading Protein-Protein Interaction (PPI) Networks.
Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.
Researchers in Doernbecher Children's Hospital at Oregon Health & Science University will begin a Phase I clinical trial using stem cells in infants and children with a rare neurodegenerative disorder that affects infants and children.
INVO Bioscience, Inc., a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the SEC declared its Registration Statement on Form S-1 filed on December 21, 2009 effective on December 30, 2009.
› Verified 9 days ago
| Entity Name | Tidalhealth Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619504735 PECOS PAC ID: 7113340845 Enrollment ID: O20200714000286 |
News Archive
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.
Nature Methods published (online) a comparative study of leading Protein-Protein Interaction (PPI) Networks.
Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.
Researchers in Doernbecher Children's Hospital at Oregon Health & Science University will begin a Phase I clinical trial using stem cells in infants and children with a rare neurodegenerative disorder that affects infants and children.
INVO Bioscience, Inc., a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the SEC declared its Registration Statement on Form S-1 filed on December 21, 2009 effective on December 30, 2009.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kurt Emil Wehberg, MD 100 E Carroll St, Salisbury, MD 21801-5422 Ph: (410) 546-6400 | Kurt Emil Wehberg, MD 30265 Commerce Dr Unit 103, Millsboro, DE 19966-3594 Ph: (302) 934-6514 |
News Archive
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.
Nature Methods published (online) a comparative study of leading Protein-Protein Interaction (PPI) Networks.
Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.
Researchers in Doernbecher Children's Hospital at Oregon Health & Science University will begin a Phase I clinical trial using stem cells in infants and children with a rare neurodegenerative disorder that affects infants and children.
INVO Bioscience, Inc., a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the SEC declared its Registration Statement on Form S-1 filed on December 21, 2009 effective on December 30, 2009.
› Verified 9 days ago